Compounds and methods for inhibiting fascin
AssigneesNovita Pharmaceuticals, Inc., Cornell University
InventorsXin-Yun Huang, Christy Young Shue
Life of this patent
Estimating the term…
Abstract
Provided are compounds, compositions and methods for inhibiting fascin activity or treating a condition or disorder mediated by fascin activity in a subject in need thereof.
Claims33
A method of treating a condition or disorder mediated by fascin activity in a subject in need thereof, wherein the condition or disorder is selected from the group consisting of a metastatic cancer, a neuronal disorder, neuronal degeneration, an inflammatory condition, a viral infection, a bacterial infection, lymphoid hyperplasia, Hodgkin's disease and ischemia-related tissue damage, which method comprises administering to the subject a therapeutically effective amount of at least one compound of Formula IV
- or tautomer thereof, and/or a pharmaceutically acceptable salt thereof;
- wherein
- R2 is 6- to 10-membered aryl or 5- to 10-membered heteroaryl;
- wherein the 6- to 10-membered aryl or 5-to 10-membered heteroaryl is optionally substituted with 1 to 4 R4, wherein each R4 is independently selected from the group consisting of lower alkyl, lower haloalkyl, —OH, —OR7, —SH, —SR7, —NR10R10 halo, cyano, nitro, —COH, —COR7, —CO2H, —CO2R7, —CONR10R10, —OCOR7, —OCO2R7, —OCONR10R10, —NR10COR10, —NR10CO2R10, —SOR7, —SO2R7, SO2NR10R10, phenyl (optionally substituted with lower alkyl, halo or lower haloalkyl, or —OH), and —NR10SO2R7;
- each R3 is independently selected from the group consisting of lower alkyl, lower haloalkyl, —OH, —OR7, —SH, —SR7, —NR10R10, halo, cyano, nitro, —COH, —COR7, —CO2H, —CO2R7, —CONR10R10, —OCOR7, —OCO2R7, —OCONR10R10, —NR10COR10, —NR10CO2R10, —SOR7, —SO2R7, SO2NR10R10, and —NR10SO2R7;
- m is 0, 1, 2 or 3;
- R7 is lower alkyl;
- and
- each R10 is independently hydrogen or lower alkyl, or two R10 together with the atom(s) attached thereto form a 4- to 6-membered ring;
- Y is selected from the group consisting of CF3, Cl, F and Me;
- Provided that the compound is not N-(1-(4-trifluoromethyl)benzyl)-1H-indazol-3-yl)furan-2-carboxamide.
A method of inhibiting fascin expression and/or activity, comprising administering an effective amount of a fascin inhibitor to a cell to thereby inhibit fascin expression or activity in the cell, wherein the fascin inhibitor is a compound of Formula IV
- or tautomer thereof, and/or a pharmaceutically acceptable salt thereof;
- wherein
- R2 is 6- to 10-membered aryl or 5- to 10-membered heteroaryl;
- wherein the 6- to 10-membered aryl or 5-to 10-membered heteroaryl is optionally substituted with 1 to 4 R4, wherein each R4 is independently selected from the group consisting of lower alkyl, lower haloalkyl, —OH, —OR7, —SH, —SR7, —NR10R10 halo, cyano, nitro, —COH, —COR7, —CO2H, —CO2R7, —CONR10R10, —OCOR7, —OCO2R7, —OCONR10R10, —NR10COR10, —NR10CO2R10, —SOR7, —SO2R7, SO2NR10R10, phenyl (optionally substituted with lower alkyl, halo or lower haloalkyl, or —OH), and —NR10SO2R7;
- each R3 is independently selected from the group consisting of lower alkyl, lower haloalkyl, —OH, —OR7, —SH, —SR7, —NR10R10, halo, cyano, nitro, —COH, —COR7, —CO2H, —CO2R7, —CONR10R10, —OCOR7, —OCO2R7, —OCONR10R10, —NR10COR10, —NR10CO2R10, —SOR7, —SO2R7, SO2NR10R10, and —NR10SO2R7;
- m is 0, 1, 2 or 3;
- R7 is lower alkyl;
- and
- each R10 is independently hydrogen or lower alkyl, or two R10 together with the atom(s) attached thereto form a 4- to 6-membered ring;
- Y is selected from the group consisting of CF3, Cl, F and Me provided that the compound is not N-(1-(4-trifluoromethyl)benzyl)-1H-indazol-3-yl)furan-2-carboxamide.
Dependencies are inferred from the claim text.